NCT04261075View on ClinicalTrials.gov

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

June 16, 2022

Study Completion Date

June 16, 2022

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

IPH5201

Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

BIOLOGICAL

durvalumab

Durvalumab Q3W for a maximum of 2 years

BIOLOGICAL

oleclumab

Oleclumab Q3W for a maximum of 2 years

Trial Locations (8)

1011

Research Site, Lausanne

8035

Research Site, Barcelona

28027

Research Site, Madrid

28078

Research Site, Huntersville

33076

Research Site, Bordeaux

37203

Research Site, Nashville

94805

Research Site, Villejuif

02906

Research Site, Providence

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY